Laboratory of Pharmacology and Pathophysiology, Faculty of Pharmacy, Kindai University, Higashi-Osaka, 577-8502, Japan; Division of Emergency and Critical Care Medicine, Fukuoka University, Hospital, Fukuoka, 814-0180, Japan.
Laboratory of Pharmacology and Pathophysiology, Faculty of Pharmacy, Kindai University, Higashi-Osaka, 577-8502, Japan.
J Pharmacol Sci. 2020 Jun;143(2):112-116. doi: 10.1016/j.jphs.2020.03.002. Epub 2020 Mar 12.
HMGB1, a nuclear protein, once released to the extracellular space, promotes somatic and visceral pain signals. We thus analyzed the role of HMGB1 in an intravesical substance P-induced bladder pain syndrome (BPS) mouse model. Intravesical administration of substance P caused referred hyperalgesia/allodynia in the lower abdomen and hindpaw without producing severe urothelial damage, which was prevented by an anti-HMGB1-neutralizing antibody, thrombomodulin α capable of inactivating HMGB1 and antagonists of RAGE or CXCR4. The HMGB1 inactivation or RAGE blockade also reversed the established bladder pain symptoms. HMGB1 and RAGE are thus considered to serve as therapeutic targets for BPS.
高迁移率族蛋白 B1(HMGB1)是一种核蛋白,一旦被释放到细胞外空间,就会促进躯体和内脏痛觉信号的产生。因此,我们分析了 HMGB1 在膀胱内 P 物质诱导的膀胱疼痛综合征(BPS)小鼠模型中的作用。膀胱内给予 P 物质会导致下腹部和后脚出现牵涉性痛觉过敏/感觉异常,而不会产生严重的尿路上皮损伤,这种损伤可以被抗 HMGB1 中和抗体、能够使 HMGB1 失活的血栓调节蛋白α以及 RAGE 或 CXCR4 的拮抗剂所预防。HMGB1 失活或 RAGE 阻断也可逆转已建立的膀胱疼痛症状。因此,HMGB1 和 RAGE 被认为是 BPS 的治疗靶点。